According to the third phase of clinical trail conducted by researchers at St. Jude Children's Research Hospital it was found that a weekly dose of erythropoietin (EPO) is a very effective treatment for children suffering from cancer who develop anemia during chemotherapy.
EPO is a natural hormone that stimulates production of hemoglobin. It reduces the need for red blood cell (RBC) transfusions in these children. This is the first large-scale study of anemic children with cancer that randomly assigned patients to receive either EPO or a placebo (inactive 'drug') intravenously, and the first to measure the effect of EPO on quality of life in children, according to Bassem Razzouk, M.D., an associate member of the Department of Oncology at St. Jude.
Razzouk is the lead author of a report on this study that appears in the August 1 issue of the Journal of Clinical Oncology. 'EPO was already known to benefit adults with cancer by increasing their hemoglobin level and improving their quality of life,' Razzouk said. 'But even though many children with cancer are anemic, there has been little evidence to support the use of EPO in such children who are receiving chemotherapy.'
The study, which was led by St. Jude, was conducted at 26 sites in the United States and included anemic patients 5 to 18 years of age who were receiving chemotherapy for solid tumors (excluding brain tumors), lymphoma and leukemia. A total of 111 patients received EPO and 111 received a placebo. The researchers studied the effect of EPO treatment on quality of life using a test called the Pediatric Quality of Life InventoryTM 4.0 Generic Core Scales (PedsQLTM-GCS), a survey that includes questions on physical, emotional and social functioning as well as school performance. The team concluded that EPO increases Hb levels in children with anemia, reduces their need for transfusions and improves the quality of life in those who have an increase in Hb.